CGEM

← Markets

CGEMCullinan Therapeutics, Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Fri, Aug 7
7:16 AMYahooThe Bull Case For Cullinan Therapeutics (CGEM) Could Change Following FDA-Backed Phase 2 CLN-049 Trial
Thu, Aug 6
6:00 AMYahooCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Wed, Jul 29
7:16 PMYahooCullinan Therapeutics (CGEM) Advances CLN 049 After FDA Feedback, Is The Upside Already Priced In?
Tue, Jul 28
6:00 AMYahooCullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
Tue, Jun 23
4:06 AMYahooCullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes
Wed, Jun 10
6:30 AMYahooCullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Sat, Jun 6
4:15 AMYahooCullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Tue, May 26
6:00 AMYahooCullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
Tue, May 19
6:00 AMYahooCullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Mon, May 18
4:00 PMYahooCullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Thu, May 7
6:00 AMYahooCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results